Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for NMB Reversal on Arrhythmias
NCT04720573Completed
- Sponsor
- Başakşehir Çam & Sakura City Hospital
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Başakşehir Çam & Sakura City Hospital. Primary endpoint: Significant arrhythmic event at 12 hours. Started Jun 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04720573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720573.